//
Skip Navigation
 
 
 
 
 
Print This Page
Share this page: More
 

Dr. Daniel Chan

Ph.D.
(410)955-2674 (p)
(410)955-0767 (f)
Categories

Proteomics, Clinical Chemistry, Biochemical Tumor Markers - Particularly Breast and Prostate Tumor Makers, Immunoassay.

Titles

Professor of Pathology, Oncology, Radiology, and Urology
Director, Center for Biomarker Discovery
 

Schools\Degrees

Ph.D., State University of New York at Buffalo, Buffalo, NY

Training

Teaching and Research Instructor, Dept. of Biochemistry, State University of New York at Buffalo, Buffalo, NY.

Postdoctoral training in Clinical Chemistry, Erie County Laboratories Meyer Hospital.
 

Certifications

American Board of Clinical Chemistry

Clinical Interests

Proteomics, Clinical Chemistry, Biochemical Tumor Markers - Particularly Breast and Prostate Tumor Makers, Immunoassay.
 

Research Summary

The focus of Dr. Chan's research is the development and application of proteomic and immunologic techniques in the diagnosis, management, and understanding of cancer. His work has demonstrated the importance of analytical methodologies for tumor markers, endocrine or clinical chemistry assays to determine the clinical outcomes of a patient?s disease process. He is an internationally recognized expert in immunoassay, clinical proteomics, and biochemical tumor markers, particularly prostate, breast and ovarian cancer biomarkers. He has edited and written five books on immunoassay, immunoassay automation, diagnostic endocrinology, and tumor markers. Dr. Chan has published over 200 articles including the tumor markers chapters in the Tietz Textbook of Clinical Chemistry and in Tumor Markers: Physiology, Pathobiology, Technology, and Clinical Applications, which he also co-edited. Dr. Chan is actively involved in the Human Proteome Organization (HUPO) and its Plasma Proteome Initiative. He serves as chairman of a HUPO committee responsible for the development of reference specimens for a global comprehensive study of the human proteome.

Journal Citations

Rogers, C.G.; Gonzalgo, M.L.; Yan, G.; Bastian, P.J.; Chan, D.Y.; Nelson, W.G.; Pavlovich, C.P. High concordance of gene methylation in post-digital rectal examination and post-biopsy urine samples for prostate cancer detection. J Urol. 2006 Nov;176(5):2280-2284.

Argani, P.; Olgac, S.; Tickoo, S.K.; Goldfischer, M.; Moch, H.; Chan, D.Y.; Eble, J.N.; Bonsib, S.M.; Jimeno, M.; Lloreta, J.; Billis, A.; Hicks, J.; De Marzo, A.M.; Reuter, V.E.; Ladanyi, M. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol. 2007 Aug;31(8):1149-1160.

Leman, E.S.; Cannon, G.W.; Trock, B.J.; Sokoll, L.J.; Chan, D.W.; Mangold, L.; Partin, A.W.; Getzenberg, R.H. EPCA-2: a highly specific serum marker for prostate cancer. Urology. 2007 Apr;69(4):714-720.

Liang, S.L.; Chan, D.W. Enzymes and related proteins as cancer biomarkers: a proteomic approach. Clin Chim Acta. 2007 May;381(1):93-97.

Borowitz, M.; Westra, W.H.; Illei, P.B.; Cooley, L.D.; Kant, J.A.; Sokoll, L.J.; Chan, D.W.; Sanfilippo, F. Pathology and Laboratory Medicine. In: Abeloff; Armitage; Kastan; Niederhuberl, editors. 4th ed, Clinical Oncology. Philadelphia: W.B. Saunders; 2008.

Leman, E.S.; Schoen, R.E.; Magheli, A.; Sokoll, L.J.; Chan, D.W.; Getzenberg, R.H. Evaluation of colon cancer-specific antigen 2 as a potential serum marker for colorectal cancer. Clin Cancer Res. 2008 Mar 1;14(5):1349-1354.

Loeb, S.; Chan, D.W.; Sokoll, L.; Kan, D.; Maggiore, J.; Mikolajczyk, S.D.; Mondo, D.M.; Griffin, C.R.; Catalona, W.J. Prostate specific antigen assay standardization bias could affect clinical decision making. J Urol. 2008 Nov;180(5):1959-1962; discussion 1962-1953.

McLerran, D.; Grizzle, W.E.; Feng, Z.; Bigbee, W.L.; Banez, L.L.; Cazares, L.H.; Chan, D.W.; Diaz, J.; Izbicka, E.; Kagan, J.; Malehorn, D.E.; Malik, G.; Oelschlager, D.; Partin, A.; Randolph, T.; Rosenzweig, N.; Srivastava, S.; Srivastava, S.; Thompson, I.M.; Thornquist, M.; Troyer, D.; Yasui, Y.; Zhang, Z.; Zhu, L.; Semmes, O.J. Analytical Validation of Serum Proteomic Profiling for Diagnosis of Prostate Cancer: Sources of Sample Bias. Clin Chem. 2008 Jan;54(1):44-52.

McLerran, D.; Grizzle, W.E.; Feng, Z.; Thompson, I.M.; Bigbee, W.L.; Cazares, L.H.; Chan, D.W.; Dahlgren, J.; Diaz, J.; Kagan, J.; Lin, D.W.; Malik, G.; Oelschlager, D.; Partin, A.; Randolph, T.W.; Sokoll, L.; Srivastava, S.; Srivastava, S.; Thornquist, M.; Troyer, D.; Wright, G.L.; Zhang, Z.; Zhu, L.; Semmes, O.J. SELDI-TOF MS Whole Serum Proteomic Profiling with IMAC Surface Does Not Reliably Detect Prostate Cancer. Clin Chem. 2008 Jan;54(1):53-60.

Meany, D.L.; Chan, D.W. Comparability of tumor marker immunoassays: still an important issue for clinical diagnostics? Clin Chem Lab Med. 2008 Nov;46(5):575-576.

Sokoll, L.J.; Wang, Y.; Feng, Z.; Kagan, J.; Partin, A.W.; Sanda, M.G.; Thompson, I.M.; Chan, D.W. [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J Urol. 2008 Aug;180(2):539-543; discussion 543.

Sturgeon, C.M.; Duffy, M.J.; Stenman, U.H.; Lilja, H.; Brunner, N.; Chan, D.W.; Babaian, R.; Bast, R.C., Jr.; Dowell, B.; Esteva, F.J.; Haglund, C.; Harbeck, N.; Hayes, D.F.; Holten-Andersen, M.; Klee, G.G.; Lamerz, R.; Looijenga, L.H.; Molina, R.; Nielsen, H.J.; Rittenhouse, H.; Semjonow, A.; Shih Ie, M.; Sibley, P.; Soletormos, G.; Stephan, C.; Sokoll, L.; Hoffman, B.R.; Diamandis, E.P. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008 Dec;54(12):e11-79.

Fujita, K.; Ewing, C.M.; Chan, D.Y.; Mangold, L.A.; Partin, A.W.; Isaacs, W.B.; Pavlovich, C.P. Endoglin (CD105) as a urinary and serum marker of prostate cancer. Int J Cancer. 2009 Feb 1;124(3):664-669.

Loeb, S.; Schaeffer, E.M.; Chan, D.W.; Carter, H.B.; Walsh, P.C.; Sokoll, L.J. Investigation of human anti-mouse antibodies as potential cause of postprostatectomy PSA elevation. Urology. 2009 May;73(5):947-949.

Meany, D.L.; Sokoll, L.J.; Chan, D.W. Early Detection of Cancer: Immunoassays for Plasma Tumor Markers. Expert Opin Med Diagn. 2009 Nov 1;3(6):597-605.

Meany, D.L.; Zhang, Z.; Sokoll, L.J.; Zhang, H.; Chan, D.W. Glycoproteomics for prostate cancer detection: changes in serum PSA glycosylation patterns. J Proteome Res. 2009 Feb;8(2):613-619.

Rosenzweig, C.N., Zhang, Z., Sun, X., Sokoll, L.J., Osborne, K., Partin, A.W., and Chan, D.W. Predicition of biochemcial recurrence of prostate cancer using a panel of serum proteomic biomarkers. J Urol. 2009;181(3):1407-1414.

Rosenzweig, C.N.; Zhang, Z.; Sun, X.; Sokoll, L.J.; Osborne, K.; Partin, A.W.; Chan, D.W. Predicting prostate cancer biochemical recurrence using a panel of serum proteomic biomarkers. J Urol. 2009 Mar;181(3):1407-1414.

Zhou, J.; Trock, B.; Tsangaris, T.N.; Friedman, N.B.; Shapiro, D.; Brotzman, M.; Chan-Li, Y.; Chan, D.W.; Li, J. A unique proteolytic fragment of alpha1-antitrypsin is elevated in ductal fluid of breast cancer patient. Breast Cancer Res Treat. 2009 Nov 10.

Sokoll, L.J.; Sanda, M.G.; Feng, Z.; Kagan, J.; Mizrahi, I.A.; Broyles, D.L.; Partin, A.W.; Srivastava, S.; Thompson, I.M.; Wei, J.T.; Zhang, Z.; Chan, D.W. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev. 2010 May;19(5):1193-1200.

Li, Y.; Tian, Y.; Rezai, T.; Prakash, A.; Lopez, M.F.; Chan, D.W.; Zhang, H. Simultaneous analysis of glycosylated and sialylated prostate-specific antigen revealing differential distribution of glycosylated prostate-specific antigen isoforms in prostate cancer tissues. Anal Chem. 2011 Jan 1;83(1):240-245.

 

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424

NCI CCC

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer